Vivos Therapeutics (VVOS)

Executive Summary

Vivos Therapeutics is a publicly traded medical device company focused on non-surgical oral appliances for obstructive sleep apnea (OSA). Its FDA-cleared devices, such as the DNA appliance and mRNA appliance, aim to rehabilitate the airway and address craniofacial structure, offering a time-limited alternative to lifelong CPAP therapy. The company targets both adults and pediatric patients with moderate to severe OSA, leveraging its digital health platform for treatment planning and monitoring. As a small-cap company (valuation ~$9M), Vivos faces significant challenges in market adoption, reimbursement, and competition from established CPAP and surgical treatments. However, its novel approach and potential to disrupt the OSA treatment market underpin its long-term opportunity. Recent performance has been mixed, with revenue growth but ongoing losses. Key milestones include expanding insurance coverage and gaining regulatory approvals in international markets. The company's ability to scale commercial operations, secure strategic partnerships, and demonstrate clinical efficacy through peer-reviewed studies will be critical for value creation. While the market is large and underserved by non-invasive alternatives, Vivos must navigate execution risks and capital constraints to achieve profitability.

Upcoming Catalysts (preview)

• Q2 2027FDA Clearance for Pediatric OSA Indication60% success
• Q1 2027Positive Results from Pivotal Clinical Trial on Adult OSA55% success
• Q3 2026Major Insurance Coverage Agreement or Reimbursement Update45% success